Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 06 2020 - 8:17AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a
clinical-stage gene therapy company utilizing a unique, non-viral
proprietary platform designed to deliver tumor suppressor genes to
cancer cells, announced that it received notice from The Nasdaq
Stock Market LLC ("Nasdaq") on February 4, 2020 indicating that the
Company has regained compliance with the minimum bid price
requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price
Rule") for continued listing on The Nasdaq Capital Market.
Accordingly, the Company has regained compliance with the Bid Price
Rule and Nasdaq considers the matter closed.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer
patients based upon a unique proprietary technology platform.
Genprex’s platform technologies are designed to administer
cancer-fighting genes by encapsulating them into nanoscale hollow
spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells, where they express
proteins that are missing or found in low quantities. The company’s
lead product candidate, Oncoprex™ immunogene therapy for non-small
cell lung cancer (NSCLC), has a multimodal mechanism of action
whereby it has been shown to interrupt cell signaling pathways that
cause replication and proliferation of cancer cells; re-establish
pathways for apoptosis, or programmed cell death, in cancer cells;
and modulate the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. In
January 2020, the FDA granted Fast Track Designation for Oncoprex™
immunogene therapy for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®). For more information, please
visit the company’s web site at www.genprex.com or follow Genprex
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Oncoprex™ immunogene therapy, alone and in
combination with targeted therapies and/or immunotherapies, on
cancer, and regarding our current and planned clinical trials.
Risks that contribute to the uncertain nature of the
forward-looking statements include the presence and level of the
effect of Oncoprex™ immunogene therapy, alone and in combination
with targeted therapies and/or immunotherapies, on cancer; the
timing and success of our clinical trials and planned clinical
trials of Oncoprex™, alone and in combination with targeted
therapies and/or immunotherapies, and our other potential product
candidates; and the timing and success of obtaining FDA approval of
Oncoprex™ and our other potential product candidates. These and
other risks and uncertainties are described more fully under the
caption “Risk Factors” and elsewhere in our filings and reports
with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200206005288/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024